Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Regeneron Pharmaceuticals Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19.48 (market cap $8.95B), while Regeneron Pharmaceuticals Inc trades at $675 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.9× Norwegian Cruise Line Holdings Ltd's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | REGN | |
|---|---|---|
Market Cap | $8.95B | $70.47B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $812.27 |
52-Week Low | $14.79 | $545.46 |
Enterprise Value | $23.92B | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $19.45, down slightly by 0.05%, with a neutral technical signal and bearish moving averages. The company reported revenue of $9.83B in 2025, with net income of $423.25M and a profit margin of 4.3%. Recent quarters show consistent earnings beats, including Q1 2026 EPS of $0.23 versus $0.15 expected. Analyst consensus is bullish with a $20.82 price target, and cash flow trends improved to a positive net of $19M in 2025.
The outlook for NCLH is cautiously optimistic, supported by earnings momentum and analyst buy ratings, but risks include high debt levels and macroeconomic sensitivity. Investment opportunity lies in continued operational recovery and potential upside to price targets, while volatility from fuel costs and travel demand poses challenges.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
